

CONSOLIDATED					Sr. No.	Particulars	COMPANY				
Rupees in Lacs [except for share data]							Rupees in Lacs [except for share data]				
3 Months Period ended on December 31, 2009 [Unaudited]	Corresponding 3 Months Period ended on December 31, 2008 [Unaudited]	9 Months Period ended on December 31, 2009 [Unaudited]	Corresponding 9 Months Period ended on December 31, 2008 [Unaudited]	Previous Accounting Year ended on March 31, 2009 [Audited]			3 Months Period ended on December 31, 2009 [Unaudited]	Corresponding 3 Months Period ended on December 31, 2008 [Unaudited]	9 Months Period ended on December 31, 2009 [Unaudited]	Corresponding 9 Months Period ended on December 31, 2008 [Unaudited]	Previous Accounting Year ended on March 31, 2009 [Audited]
97,367	75,048	278,826	220,686	291,711	1	Sales & Income from operations :					
827	1,421	2,997	4,701	5,471	A	Gross Sales	46,527	37,804	142,426	130,134	
96,540	73,627	275,829	215,985	286,240	B	Less : Excise Duty	487	994	1,708	3,343	
2,556	1,283	8,199	4,424	6,509	C	Net Sales	46,040	36,810	140,718	126,791	
99,096	74,910	284,028	220,409	292,749	D	Other Income from Operations	15,302	6,690	44,594	19,004	
					E	Total sales and other income from operations	61,342	43,500	185,312	145,795	
(2,017)	(3,773)	(6,290)	(7,515)	(4,607)	2	Expenditure :					
25,027	19,572	69,937	51,359	66,946	A	Increase [-] / Decrease [+] in stock in trade & work in progress	(1,230)	(620)	790	(830)	
7,287	8,618	25,129	27,608	33,320	B	Consumption of materials	17,182	14,895	49,743	37,761	
11,872	9,606	33,238	27,711	35,208	C	Purchase of traded goods	2,578	748	7,201	10,808	
3,336	2,994	9,410	8,042	11,182	D	Employees cost	7,051	5,435	20,264	17,259	
35,933	26,643	100,082	75,583	101,304	E	Depreciation & Amortisation	2,239	2,125	6,540	5,973	
81,438	63,660	231,506	182,788	243,353	F	Other Expenditure	20,755	12,340	61,061	49,113	
17,658	11,250	52,522	37,621	49,396	G	Total Expenditure	48,575	34,923	145,599	120,084	
246	1,169	1,079	1,603	2,036	3	Profit from Operations before Other Income, Interest & Exceptional Items [1 - 2]	12,767	8,577	39,713	25,711	
17,904	12,419	53,601	39,224	51,432	4	Other Income	1,130	2,562	3,504	5,074	
2,168	2,504	6,517	5,379	9,778	5	Profit before Interest & Exceptional Items [3 + 4]	13,897	11,139	43,217	30,785	
(383)	1,108	11	3,560	2,270	6 A	Interest & financial charges	1,035	1,840	3,357	4,052	
1,785	3,612	6,528	8,939	12,048	B	Gain [-] / Loss [+] on Exchange Rate Fluctuations on Foreign Currency Loans	(150)	625	172	1,399	
16,119	8,807	47,073	30,285	39,384	C	Total Financial cost	885	2,465	3,529	5,451	
(114)	0	(464)	(182)	(2,408)	7	Profit after Interest but before Exceptional Items [5 - 6]	13,012	8,674	39,688	25,334	
16,005	8,807	46,609	30,103	36,976	8	Exceptional Items [+] Income / [-] Expense	0	0	0	0	
2,550	2,835	6,730	5,076	6,658	9	Profit [+] / Loss [-] from Ordinary Activities before tax [7 + 8]	13,012	8,674	39,688	25,334	
13,455	5,972	39,879	25,027	30,318	10	Tax expense	480	1,450	2,460	3,000	
0	0	0	0	0	11	Net Profit [+] / Loss [-] from Ordinary Activities after tax [9 - 10]	12,532	7,224	37,228	22,334	
13,455	5,972	39,879	25,027	30,318	12	Extraordinary items [net of tax expense]	0	0	0	0	
(488)	81	(1,241)	(519)	(10)	13	Net Profit [+] / Loss [-] for the period [11 - 12]	12,532	7,224	37,228	22,334	
12,967	6,053	38,638	24,508	30,308	14	Adjustments on consolidation [+] Income / [-] Expense	0	0	0	0	
6,824	6,280	6,824	6,280	6,824	15	Net Profit [+] / Loss [-] for the period [13 + 14]	12,532	7,224	37,228	22,334	
				116,700	16	Paid-up equity share capital [Face Value Rs. 5 / -]	6,824	6,280	6,824	6,280	
9.50	4.43*	28.31	17.95*	22.20	17	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year				116,460	
9.50	4.43*	28.31	17.95*	22.20	18	Earnings Per Share [EPS] [For the period - not Annualised]:					
34,406,982	35,138,950	34,406,982	35,138,950	34,629,818	A	Basic and diluted EPS before Extraordinary items [Rs.]	9.18	5.29*	27.27	16.36*	
25.21%	27.97%	25.21%	27.97%	25.37%	B	Basic and diluted EPS after Extraordinary items [Rs.]	9.18	5.29*	27.27	16.36*	
					19	Public shareholding :					
						- Number of shares	34,406,982	35,138,950	34,406,982	35,138,950	
						- Percentage of Shareholding	25.21%	27.97%	25.21%	27.97%	
					20	Promoters and Promoter group Shareholding :					
					A	Pledged / Encumbered :					
						- Number of Shares	Nil	Nil	Nil	Nil	
						- Percentage of shares [as a % of the total shareholding of promoters and promoter group]	N.A.	N.A.	N.A.	N.A.	
						- Percentage of shares [as a % of the total share capital of the company]	N.A.	N.A.	N.A.	N.A.	
					B	Non-encumbered :					
102,092,031	90,474,758	102,092,031	90,474,758	101,869,195		- Number of Shares	102,092,031	90,474,758	102,092,031	90,474,758	
100%	100%	100%	100%	100%		- Percentage of shares [as a % of the total shareholding of promoters and promoter group]	100%	100.00%	100%	100.00%	
74.79%	72.03%	74.79%	72.03%	74.63%		- Percentage of shares [as a % of the total share capital of the company]	74.79%	72.03%	74.79%	74.63%	

- Notes :**
- [1] Pursuant to the amendments to Clause 41 of the Listing Agreement, the Company has opted to publish only the consolidated results of the Company. Investors can view the standalone results of the Company on the Company's website : www.zyduscadila.com and/or on the websites of BSE [www.bseindia.com] and/or NSE [www.nseindia.com].
- [2] The above results for the quarter / nine months period ended on December 31, 2009 were reviewed by the Audit Committee and then approved by the Board of Directors at their meeting held on January 25, 2010 and the Statutory Auditors of the Company have carried out limited review of the financial results of the Company for the quarter / nine months period ended on December 31, 2009.
- [3]* Earning per share in item 18 A & B for the quarter / nine months period ended on December 31, 2008 is calculated taking into account the allotment of additional shares issued by the Company pursuant to composite scheme of arrangement, to make the figures comparable.
- [4] During the Quarter ;
- a Zydus Healthcare S. A. (Pty.) Limited, South Africa, (ZHSA) a wholly owned subsidiary Company has acquired balance 30 % shareholding of Simayla Pharmaceuticals (Proprietary) Limited, South Africa (Simayla). Pursuant to this acquisition, Simayla has become a wholly owned subsidiary of ZHSA.
- b ZHSA has acquired a one share Company namely, Newshelf (1034) Pty. Limited, South Africa and changed its name to ZC Pharma Pty. Limited
- c Dialforhealth India Limited, (DIL) a wholly owned subsidiary Company has acquired 50% shares of Dialforhealth Greencross Limited (DGL) pursuant to termination of the Joint Venture Agreement by DIL with Greencross Healthcare Private Limited. Pursuant to this acquisition, DGL has become a wholly owned subsidiary Company of DIL.
- [5] The status of investor complaints :
- Pending at the beginning of the quarter - Nil, received and disposed off during the quarter - 23, pending at the end of the quarter - Nil.
- [6] The Company has one segment of activity viz. " Pharmaceuticals ".
- [7] The standalone figures of Cadila Healthcare Limited for the current quarter are not comparable with the figures of corresponding quarter of previous year because of demerger of Consumer Products Division, which got merged with Zydus Wellness Limited, a subsidiary of Cadila Healthcare Limited.

 By Order of the Board,
 For Cadila Healthcare Limited

 Pankaj R. Patel
 Chairman & Managing Director

Mumbai, January 25, 2010.